Background: For women with ductal carcinoma in situ (DCIS), radiation therapy after conservative surgery lowers the risk of recurrence. However, emerging evidence suggests that radiation therapy confers only a marginal absolute benefi t for older women with DCIS. In a cohort of older women with DCIS, we sought to determine whether radiation therapy was associated with a clinically signifi cant benefi t. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) -Medicare database from January 1, 1992, through December 31, 1999, we identifi ed 3409 women aged 66 years or older treated with conservative surgery for DCIS. A proportional hazards model tested whether radiation therapy was associated with a lower risk of a combined outcome, defi ned as a subsequent ipsilateral in situ or invasive breast cancer reported by SEER and/or a subsequent mastectomy reported by Medicare claims. The 5-year event risk was determined for patients without and with high-risk features, which were defi ned as at least one of the following: age 66 -69 years, tumor larger than 2.5 cm, comedo histology, and/or high grade. All statistical tests were two-sided. Results: Radiation therapy was associated with a lower risk for each component of the combined outcome (hazard ratio = 0.32, 95% confi dence interval [CI] = 0.24 to 0.44). For high-risk patients, the 5-year event risk was 13.6% without radiation therapy versus 3.8% with radiation therapy (difference = 9.8%, 95% CI = 6.5 to 13.2; P <.001). For low-risk patients, the 5-year event risk was 8.2% without radiation therapy versus 1.0% with radiation therapy (difference = 7.2%, 95% CI = 3.6 to 10.9; P <.001). Among healthy women aged 66 -79 years, the number needed to treat with radiation therapy to prevent one event in 5 years was 11 for high-risk patients and 15 -16 for low-risk patients. Conclusion: For older women with DCIS, radiation therapy appears to confer a substantial benefi t that remains meaningful even among low-risk patients. [J Natl Cancer Inst 2006;98: 1302 -10 ]
patient group ( 11 , 12 ) , but emerging evidence reveals that older women experience a low risk of recurrence ( 13 -16 ) and that radiation therapy confers only a marginal benefi t for the risk of recurrence ( 9 ) , suggesting that older women may not need radiation therapy.
We therefore used the Surveillance, Epidemiology, and End Results (SEER) -Medicare data from January 1, 1992, through December 31, 1999 , to explore whether radiation therapy after conser vative surgery was associated with a clinically signifi cant reduction in the risk of a second breast cancer event, defi ned as 1) subsequent ipsilateral in situ or invasive breast cancer reported by SEER and/or 2) subsequent mastectomy reported by Medicare claims.
P ATIENTS AND M ETHODS

Data Source and Study Sample
The National Cancer Institute's (NCI's) SEER -Medicare database tracks incident malignancies among Medicare benefi ciaries who reside in 11 geographic regions representing 14% of the US population ( 17 ) . During the study period from January 1, 1992, through December 31, 1999 , 9208 women aged 66 years or older were diagnosed with noninvasive breast cancer at the age of 66 years or older. All cases of breast cancer were pathologically confi rmed, none had evidence of spread to the lymph nodes or distant metastasis, and none were bilateral. Patients were excluded for the following reasons: histology not consistent with ductal origin (n = 558), initial surgical treatment with either biopsy examination only or mastectomy (n = 3183), and history of prior malignancy (n = 160), leaving 5510 women who met all clinical entrance criteria (patients could be excluded for more than one reason).
Within this clinical group, patients with a second primary cancer diagnosed within 9 months of the index primary were excluded (n = 147) because billing records could not discriminate between procedures performed for the index cancer versus the second cancer. Patients with inadequate Medicare records (339 without Part A and Part B coverage and 1538 without fee-for-service coverage from 12 months before diagnosis to 9 months after diagnosis) were also excluded.
Medicare claims do not consistently report laterality of breast surgery. Because we sought to determine whether radiation therapy lowered the risk of subsequent ipsilateral mastectomy, we excluded patients with unknown laterality at initial diagnosis (n = 6) and patients who developed a contralateral breast cancer (n = 159), leaving 3409 patients for the analysis.
Outcomes
Patients were considered to be at risk for any outcome during the follow-up period, which began 9 months after diagnosis and continued through December 31, 2002 . The primary outcome -a second breast cancer event -was defi ned as 1) a second, pathologically confi rmed, ipsilateral in situ breast cancer reported by SEER; 2) a subsequent, pathologically confi rmed, ipsilateral invasive breast cancer reported by SEER ( 18 ) ; and/or 3) a subsequent mastectomy reported by Medicare claims data. The secondary outcome was a repeat breast-conserving surgery procedure reported by Medicare claims data. Breast-conserving surgery performed after the initial treatment period was not included as a primary outcome because it may be performed as a biopsy procedure and is therefore not specifi c for recurrence.
Covariates
In accordance with prior studies, the initial treatment period was defi ned as the fi rst 9 months after diagnosis ( 19 48 and CPT codes 19180, 19182, 19200, 19220, or 19240 ) ( 20 -24 ) . The most extensive surgical procedure reported by SEER or Medicare during the initial treatment period was considered the defi nitive surgery. Method of axillary lymph node assessment was determined from SEER data. Treatment with radiation therapy was determined from both SEER and Medicare claims (ICD-9 Procedure codes 92.21 -92.27 or 92.29; ICD-9 Diagnosis codes V58.0, V66.1, or V67.1; CPT codes 77401 -77525 or 77761 -77799; or Revenue Center Codes 0330 or 0333) ( 19 , 21 -25 ) . Patients were considered to have received radiation therapy if either SEER or Medicare claims reported treatment with radiation therapy during the initial treatment period. Treatment with adjuvant endocrine therapy was not reported.
Patient characteristics included age at diagnosis, race (white, black, white Hispanic, Asian -Pacifi c Islander, or other -unknown), year of diagnosis, marital status (widowed, married, single, separated -divorced, or unknown), SEER registry, urban versus rural residence (large metropolitan, metropolitan, urban, small urban, or rural), median income of census tract or ZIP code ( 26 ) , percentage of adults in census tract or ZIP code with less than 12 years education ( 26 ) , and number of physician visits on separate days spanning an interval before diagnosis of 12 months to 1 month. A modifi ed Charlson comorbidity index was calculated from Part A and Part B claims for an interval before diagnosis of 12 months to 1 month ( 27 -29 ) . To enhance specifi city, Part B diagnosis codes were included only if they appeared more than once over a period exceeding 30 days or in Part A claims as well ( 30 , 31 ) .
Tumor characteristics included size, grade (low, intermediate, high -undifferentiated, or unknown), histology (ductal not otherwise specifi ed, comedo, papillary, cribriform, ductal with a lobular in situ component, or other) ( 32 ) , and laterality (right or left). Tumor size as reported by SEER was determined from the pathology report, operative note, physical examination, mammogram, and ultrasound, with highest priority given to the pathology report and lowest priority given to the ultrasound. Margin status was not reported. The Hospital Cost Report Information Systems data were used to determine the teaching status of the hospital in which the initial surgery was performed ( 33 ) .
Statistical Analysis
The risk of an event was estimated with the Kaplan -Meier method. Patients were censored at the time of death, loss of feefor-service coverage, or loss of Medicare coverage. If none of these occurred, patients were censored at the end of 2002.
A Cox proportional hazards model was used to determine the relationship between radiation therapy and the risk of an event (defi ned as a subsequent ipsilateral in situ or invasive breast cancer reported by SEER and/or a subsequent mastectomy reported by Medicare claims) after adjusting for age, race, urban -rural status, median income, marital status, comorbidity, size, histology, and grade (age and comorbidity were included due to clinical relevance; all other included variables had a univariate association with outcome at a P of . 25 or less in unadjusted analysis). Age and size were treated as continuous variables on the basis of their linearity with outcomes. Missing values for all covariates were entered as dummy categories. The model was stratifi ed by SEER registry and year of diagnosis to account for variations with geography and time. To evaluate the proportional hazards assumption, the logarithms of the hazard functions for the radiation therapy and no radiation therapy groups were compared by visual inspection. Prespecifi ed interaction terms were tested to determine whether the effect of radiation therapy varied with respect to age, size, histology, and grade. The analysis was repeated by use of a propensity score (i.e., the adjusted probability of receiving radiation therapy) to pair treated and untreated patients by use of a 1 : 1 matching algorithm ( 34 ) . The results of the propensity score analysis were not substantively different from those of the Cox model, and therefore, only results from the Cox model are presented.
A sensitivity analysis tested whether inclusion of patients with contralateral breast cancer or a change in the defi nition of the initial treatment period (from 9 months to 6 or 12 months) would alter effect sizes. In addition, we used the method proposed by Lash and Fink ( 35 ) to conduct a sensitivity analysis to determine how systematic error caused by the presence of an unmeasured confounder would alter the observed effect size of radiation therapy. We created a binary variable to represent the presence or absence of the unmeasured confounder. The population prevalence of the unmeasured confounder assumed a uniform distribution. For each subject, the combination of exposure (treatment with radiation therapy) and outcome (a second breast cancer event) determined the probability of having the unmeasured confounder. A reconstructed dataset was created that included 1000 iterations of the original dataset, with each iteration having a population prevalence that was bounded by a prespecifi ed uniform distribution. To determine how systematic error from an unmeasured confounder would alter the observed effect size of radiation therapy, a Cox model adjusted for the unmeasured confounder and the original covariates was analyzed for each iteration of the reconstructed dataset. To determine how the combination of systematic and random error would alter the observed effect size of radiation therapy, bootstrap estimates for the effect size of radiation therapy were generated by resampling with replacement from the reconstructed data set. All statistical analyses were two-sided with an α of .05 or less and were conducted by use of SAS version 9.1 (Cary, NC). The Yale Human Investigations Committee approved this study and granted a waiver of informed consent.
Patients were considered at high risk if they had any one of the following prespecifi ed risk factors: age of 66 -69 years, tumor size of larger than 2.5 cm, comedo histology, and/or high grade ( 13 ) . Patients without any of these risk factors were considered at low risk. The age cut point of 70 years was selected because current guidelines suggest that radiation therapy may be omitted for women of age 70 years or older with early invasive breast cancer ( 11 ) . A cut point of 2.5 cm was selected for size because a trial of patients with DCIS treated by lumpectomy that compares radiation therapy with observation considered a tumor size of larger than 2.5 cm to be an exclusion criteria ( 36 ) .
The adjusted number needed to treat was calculated by dividing the unadjusted number needed to treat by the survival probability point estimate ( 37 ) . The adjusted number needed to treat indicates the number of patients who require treatment with radiation therapy to prevent one event after accounting for the competing risk of death. For example, if radiation therapy conferred an 8% absolute improvement (unadjusted) in the risk of local relapse at 5 years and if 70% of patients were alive at 5 years, then the unadjusted number needed to treat would be 12.5 (i.e., 1/0.08) and the adjusted number needed to treat would be 18 (i.e., 12.5/0.70).
R ESULTS
Baseline Characteristics
Of 3409 patients identifi ed ( Table 1 ) , median age was 74 years (interquartile range = 70 -79 years), 2818 (83%) were white, and 270 (8%) were black. Median tumor size was 0.7 cm (interquartile range = 0.3 -1.2 cm), 451 (13%) of the 3409 tumors were classifi ed as high grade, and 640 (19%) were classifi ed as comedo. Comorbidity was absent in 2303 (68%) of the 3409 patients, mild in 699 (21%), and moderate to severe in 294 (9%). A total of 1676 (49%) of the 3409 patients received radiation therapy. Receipt of radiation therapy was correlated with younger age, absence of comorbidity, comedo histology, and high grade ( Table  1 ) . Concordance between SEER and Medicare claims was high for both radiation therapy (92% concordance and κ = 0.84) and surgery (92% concordance and κ = 0.85).
Unadjusted Risk of All Outcomes
Median follow-up among the 3409 patients was 5.0 years (interquartile range = 3.5 -7.0 years). During follow-up, 63 (1.9%) patients experienced a second ipsilateral in situ breast cancer, 107 (3.1%) experienced a subsequent ipsilateral invasive breast cancer, 167 (4.9%) underwent subsequent mastectomy, and 498 (15%) underwent repeat breast-conserving surgery. Radiation therapy was associated with a reduced risk for each outcome ( Table 2 and Fig. 1 ). The 5-year risk of a second breast cancer event (the combined outcome) was 10.7% for women treated with conservative surgery alone versus 3.6% for women treated with conservative surgery plus radiation therapy (difference = 7.1%, 95% confi dence interval [CI] = 5.2% to 9.0%; P <.001). Consistent results were observed if the outcome were restricted to patients with either subsequent ipsilateral invasive breast cancer or subsequent mastectomy, with a 5-year risk of 8.6% for women treated with conservative surgery alone versus 3.3% for women treated with conservative surgery plus radiation therapy (difference = 5.3%, 95% CI = 3.6% to 7.1%; P <.001). With regard to the secondary outcome of repeat breast-conserving surgery, the 5-year risk was 17.6% for women treated with conservative surgery alone versus 11.2% for women treated with conservative surgery plus radiation therapy (difference = 6.4%, 95% CI = 3.8% to 9.0%; P <.001).
Adjusted Effect of Radiation Therapy
The logarithms of the hazard functions for the radiation therapy and no radiation therapy groups were parallel, indicating that the proportional hazards assumption was satisfi ed. Radiation therapy was associated with a reduced risk of second ipsilateral in situ breast cancer (adjusted hazard ratio [HR] = 0.23, 95% CI = 0.12 to 0.45; P <.001), subsequent ipsilateral invasive breast * Radiation therapy was defi ned as any code for delivery of radiation therapy present in Medicare claims within 9 months of diagnosis or treatment with radiation therapy reported by Surveillance, Epidemiology, and End Results data. DCIS = ductal carcinoma in situ; LCIS = lobular carcinoma in situ.
† P value is from two-sided Pearson's chi-square test.
cancer (adjusted HR = 0.27, 95% CI = 0.16 to 0.45; P <.001), subsequent mastectomy (adjusted HR = 0.42, 95% CI = 0.29 to 0.60; P <.001), and any second breast cancer event (adjusted HR = 0.32, 95% CI = 0.24 to 0.44; P <.001) ( Table 3 ). Other factors predicting an increased risk of a second breast cancer event included large tumor size, comedo histology, and high grade ( Table  3 ) . Advanced age at diagnosis was associated with a lower risk of an event ( Table 3 ). The interaction of radiation therapy with these factors was not statistically signifi cant, indicating that the relative benefi t associated with radiation therapy was similar for patients at low risk and patients at high risk for an event.
The risk reduction associated with radiation therapy was not sensitive to inclusion of patients with contralateral breast cancer or to the defi nition of the initial treatment period. Inclusion of an unbalanced, unmeasured confounder reduced the effect size of radiation therapy ( Table 4 ). An unmeasured confounder with the following characteristics negated the observed reduction in risk associated with radiation therapy: 1) prevalence of 5% in the group receiving radiation therapy and of 50% in the group receiving no radiation therapy and 6.7-fold associated increase in event risk and 2) prevalence of 5% in the group receiving radiation therapy and 85% in the group receiving no radiation therapy and 3.7-fold associated increase in event risk. An unmeasured confounder that was more balanced between the two groups or was associated with a smaller effect size did not negate the statistical signifi cance of the observed relationship between radiation therapy and reduced event risk ( Table 4 ) .
Absolute Effect of Radiation Therapy by Risk Group
A total of 539 patients were low risk, 1570 patients were high risk, and 1300 patients could not be classifi ed because of missing data. Among low-risk patients, the 5-year event risk associated with conservative surgery alone was 8.2% and that associated with conservative surgery plus radiation therapy was 1.0% (difference = 7.2%, 95% CI = 3.6 to 10.9; P <.001). Among high-risk patients, the 5-year event risk associated with conservative surgery alone was 13.6% and that associated with conservative surgery plus radiation therapy was 3.8% (difference = 9.8%, 95% CI = 6.5 to 13.2; P <.001). Among unclassifi ed patients, the 5-year event risk associated with conservative surgery alone was 9.3% and that associated with conservative surgery plus radiation therapy was 4.1% (difference = 5.2%, 95% CI = 2.2 to 8.1; P <.001) ( Table 5 and Fig. 2 ).
Number Needed to Treat and Use of Radiation Therapy
Within the high-risk group, patients of 66 -79 years with absent or mild comorbidity were most likely to benefi t from radiation therapy, with an adjusted number needed to treat of 11 patients to prevent one event in a 5-year period. For such patients, 65% actually received radiation therapy. In contrast, high-risk patients of 85 years or older with moderate to severe comorbidity were least likely to benefi t from radiation therapy, with an adjusted number needed to treat of 22. Only 27% of such patients received radiation therapy ( Table 6 ) .
Patients in the low-risk group were less likely to benefi t from radiation therapy and to receive radiation therapy than patients in the high-risk group. For low-risk patients of 70 -79 years with absent or mild comorbidity, the adjusted number needed to treat was 15 -16 patients treated with radiation therapy to prevent one event in 5 years, and only 33% -54% of such patients received radiation therapy. For low-risk patients of 85 years or older with moderate to severe comorbidity, the adjusted number needed to treat was 29, and none of these patients received radiation therapy ( Table 6 ).
D ISCUSSION
In this population-based study of older women with DCIS, radiation therapy after conservative surgery was associated with a 68% reduction in the relative risk of a second breast cancer event. The relative benefi t of radiation therapy was highly consistent -regardless of whether the endpoint was second in situ breast cancer, subsequent invasive breast cancer, or subsequent mastectomy -and persisted despite the presence or absence of accepted risk factors such as younger age at diagnosis, large tumor size, high tumor grade, and aggressive tumor histology.
The absolute benefi t associated with radiation therapy was considerable and compared favorably with that of other accepted clinical interventions. For example, 21 women with essential Table 5 . * Combined outcome of second ipsilateral in situ breast cancer, subsequent ipsilateral invasive breast cancer, and/or subsequent mastectomy. Number of women at risk at 5 and 8 years is reported in Fig. 2 . CI = confi dence interval.
† P value from two-sided log-rank test comparing radiation therapy versus no radiation therapy. ‡ All numbers are rounded to two signifi cant digits. Therefore, the absolute risk reduction may not precisely equal the difference in the reported local relapse risks for radiation therapy and no radiation therapy.
§ Low-risk group includes patients of age ≥ 70 years with tumor size of ≤ 2.5 cm, noncomedo histology, and non -high grade. High-risk group includes any of the following characteristics: age 66 -69 years, tumor size >2.5 cm, comedo histology, and/or high grade. Fig. 2 . Effect of radiation therapy (RT) in low-risk and high-risk groups. An event was defi ned as any second breast cancer event, including a second ipsilateral, pathologically confi rmed, in situ breast cancer reported by Surveillance, Epidemiology, and End Results (SEER) or a subsequent ipsilateral, pathologically confi rmed, invasive breast cancer reported by SEER, and/or a subsequent mastectomy reported by Medicare claims. A ) Low-risk group defi ned as age of 70 years or older with tumor size of ≤ 2.5 cm, noncomedo histology, and low or intermediate grade. B ) High-risk group defi ned as having at least one of the following risk factors: age of 66 -69 years, tumor size of >2.5 cm, comedo histology, or high grade. The two-sided statistical test used was the long-rank test. Vertical bars indicate 95% confi dence intervals at 5 and 8 years.
hypertension require 10 years of antihypertensive therapy to prevent one cardiac event ( 38 ) , and 36 women with osteoporosis require 3 years of bisphosphonate therapy to prevent one clinically apparent fracture ( 39 ) . Among healthy older women with DCIS, we found that 11 high-risk and 15 -16 low-risk patients required radiation therapy to prevent one event at 5 years.
These results strongly suggest that, for older women with DCIS, radiation therapy should not be denied solely on the basis of chronologic age. Rather, the decision to recommend radiation therapy should be based on two general considerations. First, an individual's risk for recurrence may be estimated, however coarsely, using established risk factors such as close or positive margins, high grade, the presence of comedo necrosis, and potentially other factors ( 9 , 13 , 15 , 40 -45 ) . Our study has confi rmed that the absolute benefi t associated with radiation therapy was greater for high-risk patients than for low-risk patients. The second consideration is an individual's risk of intercurrent death before recurrence because a patient who dies before recurrence will not benefi t from radiation therapy. We have shown that, because of differences in the risk of intercurrent death, healthy women 66 -79 years old were twice as likely to benefi t from radiation therapy than women 85 years or older who have moderate to severe comorbidity. Given the growing number of elderly cancer patients ( 46 ) , further research is urgently needed to evaluate the benefi ts of adjuvant cancer therapy within the context of age, comorbidity, and risk of intercurrent death.
During the study period, patients who were more likely to benefi t from radiation therapy were also more likely to receive radiation therapy, suggesting that rational principles inform clinical decision making in the community setting. Nevertheless, among healthy older women at low risk for intercurrent death, 30% -40% of high-risk patients and 50% -70% of low-risk patients did not receive radiation therapy. Further studies are needed to determine whether omission of radiation therapy is driven by patient pref erence or by barriers such as physician bias against radiation therapy or inadequate access to radiation therapy facilities.
Three randomized trials have demonstrated that, for women with DCIS, radiation therapy after conservative surgery lowered the risk of recurrence by 38% -62% ( 4 -6 , 47 ) . However, the vast majority of women enrolled in these trials were younger than 66 years, and outcomes for older women were not specifi cally reported. In contrast, a recent randomized trial conducted in older women with early invasive breast cancer treated with conservative surgery and tamoxifen concluded that radiation therapy may not be needed for this patient group because the absolute risk reduction conferred by radiation therapy was only 3% at 5 years ( 48 ) . Similarly, recent observational data from Silverstein ( 9 ) suggested that radiation therapy should be omitted for women 61 years or older with low-risk DCIS. In contrast, our data suggest that in the general population of older women with DCIS, ra diation therapy after conservative surgery was associated with a more substantial clinical benefi t, even for low-risk patients.
Despite its observational nature, our study has several strengths. First, it represents the largest published series to evaluate the natural history of DCIS among women 66 years or older. Second, because this study was conducted with population-based data, its results are broadly applicable and demonstrate the external validity of prior randomized trials ( 49 -52 ) . Finally, our study has confi rmed the prognostic signifi cance of pathologic factors commonly available to clinicians and therefore highlights the importance of population-based data in the study of actual, if not ideal, clinical practice.
Our study has certain limitations. For example, recurrence of in situ cancer within the ipsilateral breast may be underreported by SEER ( 17 ) . In contrast, the more clinically signifi cant endpoint of subsequent ipsilateral invasive breast cancer is more likely to be consistently reported by SEER because it represents a new histologic diagnosis. Given the potential for underreporting by SEER, we included Medicare-reported subsequent mastectomy as a marker to capture recurrence. This approach appears to have addressed possible problems with underreporting because the resulting risk of a second breast cancer event reported in our study was consistent with other large observational studies. For example, among patients treated with conservative surgery alone, our study reported a 5-year event risk of 10.7%, consistent with 5-year recurrence estimates ranging from 9% to 15.8% in previous studies ( 13 , 53 ) . Among patients treated with conservative surgery plus radiation therapy, our study reported a 5-year event risk of 3.6%, consistent with 5-year recurrence estimates ranging from 3% to 6% in previous studies ( 15 , 53 ) .
Another limitation concerns the absence of surgical margin status, a known risk factor for local recurrence ( 15 , 41 , 44 ) . However, because patients with positive margins may be more likely to receive radiation therapy, the absence of margin status would bias our results toward the null and result in the underestimation of the true benefi t of radiation therapy. Nevertheless, our results do not exclude the possibility that widely negative surgical margins may obviate the need for radiation therapy in certain groups of older women, and this issue merits further study in prospective trials ( 10 , 44 ) .
In addition, although all patients in this study had pathologically confi rmed DCIS according to SEER records, it is likely that, if each tumor was reviewed by a panel of expert breast pathologists, some tumors would be reclassifi ed as benign proliferative lesions, lobular carcinoma in situ, or invasive cancer. Therefore, the effect size of radiation therapy reported in this study may require further refi nement when applied to patients diagnosed in centers with a dedicated breast pathologist.
Finally, information on tamoxifen prescription and compliance was not available. Although tamoxifen has been shown to lower the risk of in-breast recurrence by approximately 3% at 5 years ( 54 ) , this data were not published until 1999, and therefore, it is unlikely that many patients during the study period of January 1, 1992, through December 31, 1999, received tamoxifen. Even if all the patients treated with radiation therapy also received tamoxifen, the small benefi t of tamoxifen is insuffi cient to explain the large benefi t associated with radiation therapy in this study ( 6 , 54 ) .
Our results indicate that, for older women with DCIS, radiation therapy after conservative surgery was associated with a lower risk of second ipsilateral in situ breast cancer, subsequent ipsilateral invasive breast cancer, and subsequent mastectomy. Even for low-risk patients, the benefi t of radiation therapy compared favorably with other accepted interventions. Future studies should explore whether the apparent underutilization of radiation therapy in this patient population refl ects patient preference or stems from barriers to care.
